healthcentral.com
Can We Reduce Invasive Testing to Monitor Crohn's Disease? - HealthCentral
This matters because regular ileocolonoscopies are invasive, costly, and carry risks. If fecal calprotectin reliably rules out significant recurrence for people in deep remission or with low‑risk findings, some patients may safely need scopes less often.
Adult Crohn’s patients in remission or considered low risk after surgery, gastroenterologists and IBD clinicians, and people interested in noninvasive monitoring methods.
What To Know
A recent clinical study and expert commentary discussed using fecal calprotectin (FC) testing to monitor low‑risk Crohn’s patients after surgery as a way to reduce the frequency of follow-up ileocolonoscopies.
The study followed 55 people considered low risk and collected stool FC every four months; investigators reported that two consecutive FC values below 250 µg/g (and often <100 µg/g) were associated with no endoscopic recurrence during the study window.
Experts quoted in the article note FC testing is noninvasive and cost‑effective but can give false low or high readings in certain situations (patchy small‑bowel disease, NSAIDs, infections, hemorrhoids, etc.), so results must be interpreted with clinical context.
Findings come from a single observational study with 55 participants and expert commentary; thresholds and monitoring intervals (e.g., two consecutive FC <250 µg/g) are study‑specific and not yet universal guidelines.
FC can be affected by non‑IBD factors and may miss small‑bowel, patchy inflammation, so clinicians will likely combine FC with symptoms and other tests before changing surveillance schedules.
